Avidity Biosciences, Inc. — Director's Dealing 2025

Aug 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2025-08-06

Reporting Person: LEVIN ARTHUR A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-08-06	Common Stock	M	107500	$22.34	Acquired	127150	Direct
2025-08-06	Common Stock	S	107500	$47.6175	Disposed	19650	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-08-06	Stock Option (Right to Buy)	$22.34	M	107500	Disposed	2031-02-01	Common Stock (107500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	131372	Indirect
Common Stock	22500	Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on October 17, 2024.

F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $48.02. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: This option is fully vested and exercisable as of the date of this Report.